PNTG
BULLISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Stock trades at a premium due to high growth expectations; PEG of 1.78 suggests slight overvaluation relative to growth.
- Forward P/E is reasonable at 19.39
- Price ($30.42) is well above Graham Number ($13.43)
- Price is above Intrinsic Value ($24.78)
Growth trajectory is the primary catalyst for the current valuation.
- 53%+ growth in both revenue and earnings
- Consistent earnings beats in recent quarters
- Potential for Medicare reimbursement rate cuts
The company has successfully pivoted from a period of earnings misses (2021-2022) to consistent growth.
- Strong 3Y return of 129.2%
- Significant improvement in EPS surprise trend since 2021
- Negative 5Y change (-26%)
Financial health is stable but not 'strong'; lacks an Altman Z-Score for bankruptcy risk verification.
- Piotroski F-Score of 6/9 indicates stability
- Debt/Equity of 1.23 is higher than some peers
- Quick ratio below 1.0
Company is reinvesting all capital into growth.
- No dividend payments
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PNTG and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PNTG
The Pennant Group, Inc.
Primary
|
-26.0% | +129.2% | +16.1% | +27.2% | -7.9% | -4.0% |
|
ABCL
AbCellera Biologics Inc.
Peer
|
-90.7% | -53.9% | +45.4% | -21.9% | +11.5% | +1.2% |
|
AKTS
Aktis Oncology, Inc.
Peer
|
-15.2% | -15.2% | -15.2% | -15.2% | +5.2% | +1.0% |
|
KMTS
Kestra Medical Technologies, Ltd.
Peer
|
-18.2% | -18.2% | -26.2% | -18.8% | -19.3% | -9.9% |
|
PCRX
Pacira BioSciences, Inc.
Peer
|
-62.4% | -44.9% | -2.5% | +4.8% | +8.8% | +0.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PNTG
The Pennant Group, Inc.
|
BULLISH | $1.06B | 36.21 | 9.8% | 3.1% | $30.42 | |
|
ABCL
AbCellera Biologics Inc.
|
NEUTRAL | $1.06B | - | -14.5% | -194.9% | $3.49 | Compare |
|
AKTS
Aktis Oncology, Inc.
|
BEARISH | $1.05B | - | -26.5% | -% | $18.99 | Compare |
|
KMTS
Kestra Medical Technologies, Ltd.
|
BEARISH | $1.04B | - | -92.7% | -173.0% | $17.87 | Compare |
|
PCRX
Pacira BioSciences, Inc.
|
BEARISH | $1.03B | 149.12 | 1.0% | 1.0% | $23.86 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-03 | GUERISOLI BRENT | Chief Executive Officer | Stock Award | 20,052 | - |
| 2026-03-03 | WALBOM LYNETTE B. | Chief Financial Officer | Stock Award | 14,292 | - |
| 2026-03-03 | CHENEY KIRK S. | General Counsel | Stock Award | 4,085 | - |
| 2026-03-03 | GOCHNOUR JOHN J | Chief Operating Officer | Stock Award | 18,565 | - |
| 2026-01-15 | COVEY STEPHEN M.R. | Director | Stock Award | 1,900 | - |
| 2026-01-15 | MORRIS GREGORY K. SR. | Director | Stock Award | 1,900 | - |
| 2026-01-15 | SMITH BARRY M | Director | Stock Award | 1,900 | - |
| 2026-01-15 | LAMB SCOTT E | Director | Stock Award | 2,400 | - |
| 2026-01-15 | CHRISTENSEN CHRISTOPHER R | Director | Stock Award | 1,900 | - |
| 2026-01-15 | SNAPPER SUZANNE D. | Director | Stock Award | 1,900 | - |
| 2026-01-15 | NACKEL JOHN G | Director | Stock Award | 1,900 | - |
| 2025-11-11 | CHENEY KIRK S. | General Counsel | Option Exercise | 3,800 | $57,342 |
SEC Filings
Recent regulatory filings from the SEC EDGAR database
For the year ended December 31, 2025, PNTG derived 48.4% of its revenue from the Medicare program. The company faces material risk from federal changes to Medicare reimbursement rates, caps, and rules, which could adversely affect its financial condition and influence reimbursement from other payors.
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning PNTG from our newsroom.